Loading stock data…
$55.10+0.72 (+1.33%)
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BioMarin Pharmaceutical Inc. in the Healthcare sector is trading at $55.10 with a market capitalization of $11.9B. Wall Street consensus targets $91.73 (26 analysts), implying a +66.5% move over the next 12 months. The stock is currently 22% below its 52-week high of $70.98, remaining 6.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $989.71M↑ | $766.21M↓ | $874.57M↑ | $776.13M↓ | $825.41M |
| Gross Profit | $786.91M↑ | $571.21M↓ | $598.86M↓ | $636.05M↓ | $675.32M |
| Operating Income | $110.97M↓ | $129.63M↑ | -$44.60M↑ | -$46.68M↓ | $276.87M |
| Net Income | $44.76M↓ | $105.53M↑ | -$46.57M↓ | -$30.74M↓ | $240.53M |
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Paci...